Travere Therapeutics (TVTX) on Wednesday announced the pricing of its underwritten offering of $475M aggregate principal amount of 0.50% convertible senior notes due 2032. The sale of the notes is ...
Scorpio Tankers Inc. (NYSE: STNG) (the “Company”) announced today that it priced a private offering (the “Offering”) of $200.0 million aggregate principal amount of additional 1.75% convertible senior ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...
Tempus estimates that the net proceeds from the Offering will be approximately $384.1 million (or approximately $441.9 million if the initial purchasers exercise their option to purchase additional ...
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market ...
The MarketWatch News Department was not involved in the creation of this content. WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") ...
ProPetro Holding Corp. (NYSE: PUMP) (together with its subsidiaries, “ProPetro” or the “Company”) today announced its intention to offer, subject to market and other conditions, $500,000,000 aggregate ...
Repurchasing approximately $300 million principal amount of existing convertible senior notes and removing approximately 5.2 million underlying shares as well as approximately $51.4 million of ...
Scorpio Tankers Inc. (NYSE: STNG) (the “Company”) announced today its intention to offer $150.0 million aggregate principal amount of additional 1.75% convertible senior notes due 2031 (the “New Notes ...
AST SpaceMobile intends to use the net proceeds from each Registered Direct Offering, together with cash on hand, to enter into one or more separate, privately negotiated transactions with a limited ...